{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T15:19:24Z","timestamp":1793200764306,"version":"4.5.0"},"reference-count":66,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>KMT2A-rearranged (KMT2A-r) acute leukemias are especially prevalent in the pediatric population. KMT2A-fusion proteins drive leukemogenic gene expression through an interaction with a chromatin complex that includes the scaffold protein menin, giving rise to aggressive acute leukemias. RAS pathway mutations are also common in pediatric leukemia. In a cohort of 1750 patients enrolled on Children\u2019s Oncology Group (COG) trials, we identified RAS pathway mutations in 43% of acute myeloid leukemia (AML) cases. The presence of RAS pathway mutations in KMT2A-r AML was associated with a lower complete remission rate, poor event-free survival and overall survival (OS), and early relapses. Given the inferior outcome observed for children with dual mutations, we next sought to identify efficacious targeted drug combinations for this subset of childhood leukemia. We evaluated RAS\/MAPK targeting using the MEK1\/2 inhibitor selumetinib in combination with the menin inhibitor revumenib. Treatment of AML cell lines and cultured leukemia cells from patient-derived xenograft (PDX) models resulted in a synergistic decrease in viability and promoted cell cycle arrest, apoptosis, and downregulation of Myc targets in the combination compared with each drug alone. In vivo, the combination treatment of AML pediatric PDX models harboring KMT2A-r and RAS mutations reduced leukemia burden compared with single-drug treatments but without improving OS compared with menin inhibition alone. Our preclinical study suggests a potential targeted treatment combination for KMT2A-r and RAS pathway\u2013mutant leukemia but one that will require further optimization. These trials were registered at www.clinicaltrials.gov as NCT00070174, NCT00372593, NCT01371981, and NCT00002798.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016208","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:31:45Z","timestamp":1778009505000},"page":"4757-4771","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Combining menin and MEK inhibition to target poor prognosis\n                    <i>KMT2A<\/i>\n                    -rearranged RAS pathway\u2013mutant acute myeloid leukemia"],"prefix":"10.1182","volume":"10","author":[{"given":"Nastassja","family":"Scheidegger","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"},{"name":"2Broad Institute of MIT and Harvard, Cambridge, MA"},{"name":"3Department of Pediatric Oncology, Children\u2019s University Hospital of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0092-5999","authenticated-orcid":false,"given":"Constanze","family":"Schneider","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"},{"name":"2Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5668-6297","authenticated-orcid":false,"given":"Gabriela","family":"Alexe","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"},{"name":"2Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Cheng","family":"Wang","sequence":"additional","affiliation":[{"name":"4Children's Oncology Group, Monrovia, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Alonzo","sequence":"additional","affiliation":[{"name":"4Children's Oncology Group, Monrovia, CA"},{"name":"5Keck School of Medicine, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Basanthakumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"},{"name":"2Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace A.","family":"Bourgeois","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5094-1904","authenticated-orcid":false,"given":"Julia","family":"Dudkiewicz-Garbicz","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delan","family":"Khalid","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"},{"name":"2Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8858-2776","authenticated-orcid":false,"given":"Lucy A.","family":"Merickel","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"},{"name":"2Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Perry","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3702-7923","authenticated-orcid":false,"given":"Rhonda E.","family":"Ries","sequence":"additional","affiliation":[{"name":"6Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7112-6098","authenticated-orcid":false,"given":"Silvi","family":"Salhotra","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"},{"name":"2Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Taillon","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"},{"name":"2Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-2893","authenticated-orcid":false,"given":"Alan","family":"Gamis","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, Children's Mercy Kansas City, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7482-5644","authenticated-orcid":false,"given":"Richard","family":"Aplenc","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian H.","family":"Harris","sequence":"additional","affiliation":[{"name":"9Department of Pathology, Boston Children's Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-5146","authenticated-orcid":false,"given":"Mark","family":"Wunderlich","sequence":"additional","affiliation":[{"name":"10Division of Experimental Hematology and Cancer Biology, Cancer and Blood Disease Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.","family":"Pollard","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[{"name":"6Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-0216","authenticated-orcid":false,"given":"Yana","family":"Pikman","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"},{"name":"2Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Stegmaier","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, MA"},{"name":"2Broad Institute of MIT and Harvard, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"2026071409580614000_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fped.2017.00004","article-title":"MLL-rearranged leukemias-an update on science and clinical approaches","volume":"5","author":"Winters","year":"2017","journal-title":"Front Pediatr"},{"issue":"28","key":"2026071409580614000_bib2","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III Children's Oncology Group Trial AAML0531","volume":"39","author":"Pollard","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026071409580614000_bib3","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2026071409580614000_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"7","key":"2026071409580614000_bib5","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41375-024-02244-4","article-title":"KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia","volume":"38","author":"Iyoda","year":"2024","journal-title":"Leukemia"},{"issue":"10","key":"2026071409580614000_bib6","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1097\/HS9.0000000000000785","article-title":"Duplex sequencing uncovers recurrent low-frequency cancer-associated mutations in infant and childhood KMT2A-rearranged acute leukemia","volume":"6","author":"Pilheden","year":"2022","journal-title":"Hemasphere"},{"issue":"1","key":"2026071409580614000_bib7","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41467-018-04180-1","article-title":"De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia","volume":"9","author":"Hyrenius-Wittsten","year":"2018","journal-title":"Nat Commun"},{"issue":"9","key":"2026071409580614000_bib8","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/ng.3371","article-title":"The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias","volume":"47","author":"Lavallee","year":"2015","journal-title":"Nat Genet"},{"issue":"6","key":"2026071409580614000_bib9","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/leu.2012.365","article-title":"Secondary mutations in t(4;11) leukemia patients","volume":"27","author":"Prelle","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2026071409580614000_bib10","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/bjh.13279","article-title":"Subclonality and prenatal origin of RAS mutations in KMT2A (MLL)-rearranged infant acute lymphoblastic leukaemia","volume":"170","author":"Emerenciano","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"2026071409580614000_bib11","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.3324\/haematol.2017.174060","article-title":"Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia","volume":"103","author":"Kerstjens","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"2026071409580614000_bib12","doi-asserted-by":"crossref","first-page":"14835","DOI":"10.18632\/oncotarget.11730","article-title":"MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations","volume":"8","author":"Kerstjens","year":"2017","journal-title":"Oncotarget"},{"issue":"23","key":"2026071409580614000_bib13","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","article-title":"Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition","volume":"124","author":"Irving","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2026071409580614000_bib14","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1158\/2159-8290.CD-20-0564","article-title":"Matched targeted therapy for pediatric patients with relapsed, refractory, or high-risk leukemias: a report from the LEAP Consortium","volume":"11","author":"Pikman","year":"2021","journal-title":"Cancer Discov"},{"issue":"26","key":"2026071409580614000_bib15","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2014-05-574582","article-title":"Preclinical efficacy of MEK inhibition in Nras-mutant AML","volume":"124","author":"Burgess","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2026071409580614000_bib16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1078-0432.CCR-13-1311","article-title":"Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial","volume":"20","author":"Jain","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2026071409580614000_bib17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"2026071409580614000_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"3","key":"2026071409580614000_bib19","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov"},{"issue":"3","key":"2026071409580614000_bib20","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","article-title":"Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia","volume":"13","author":"Wang","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"2026071409580614000_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ng765","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","volume":"30","author":"Armstrong","year":"2002","journal-title":"Nat Genet"},{"issue":"11","key":"2026071409580614000_bib22","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1038\/s41375-022-01707-w","article-title":"Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1","volume":"36","author":"Fiskus","year":"2022","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2026071409580614000_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-134942","article-title":"Preliminary data on a phase 1\/2A first in human study of the menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed or refractory acute myeloid leukemia","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"issue":"16_suppl","key":"2026071409580614000_bib24","doi-asserted-by":"crossref","first-page":"TPS7079","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7079","article-title":"Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax\/azacitidine or standard induction cytarabine\/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia","volume":"41","author":"Zeidan","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7954","key":"2026071409580614000_bib25","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"7954","key":"2026071409580614000_bib26","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"issue":"18","key":"2026071409580614000_bib27","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/ITD+ acute myeloid leukemia: a report from the Children's Oncology Group Protocol AAML1031","volume":"40","author":"Pollard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026071409580614000_bib28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cncr.26190","article-title":"AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group","volume":"118","author":"Cooper","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"2026071409580614000_bib29","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2007-04-084293","article-title":"Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group","volume":"111","author":"Lange","year":"2008","journal-title":"Blood"},{"key":"2026071409580614000_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"3","key":"2026071409580614000_bib31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"2026071409580614000_bib32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0165-6147(83)90490-X","article-title":"Analysis of combined drug effects: a new look at a very old problem","volume":"4","author":"Chou","year":"1983","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"2026071409580614000_bib33","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"2026071409580614000_bib34","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","article-title":"Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies","volume":"18","author":"Kluk","year":"2016","journal-title":"J Mol Diagn"},{"issue":"9583","key":"2026071409580614000_bib35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(07)61126-X","article-title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial","volume":"370","author":"Pieters","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"2026071409580614000_bib36","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2012.067983","article-title":"Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants","volume":"98","author":"Driessen","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"2026071409580614000_bib37","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3324\/haematol.2017.185975","article-title":"Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM","volume":"104","author":"Matheson","year":"2019","journal-title":"Haematologica"},{"key":"2026071409580614000_bib38","doi-asserted-by":"crossref","first-page":"12020","DOI":"10.1038\/s41598-017-12222-9","article-title":"Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1\/2 inhibitor","volume":"20","author":"Novo","year":"2017","journal-title":"Selumetinib. Sci Rep"},{"issue":"11","key":"2026071409580614000_bib39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","article-title":"Therapeutic strategies to target RAS-mutant cancers","volume":"15","author":"Ryan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"2026071409580614000_bib40","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1093\/emboj\/17.13.3714","article-title":"Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b","volume":"17","author":"Evert","year":"1998","journal-title":"EMBO J"},{"issue":"1","key":"2026071409580614000_bib41","article-title":"Overexpression of the myeloid leukemia\u2013associated Hoxa9 gene in bone marrow cells induces stem cell expansion","volume":"99","author":"Unnur","year":"2002","journal-title":"Blood"},{"issue":"47","key":"2026071409580614000_bib42","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1038\/sj.onc.1210760","article-title":"Hox genes in hematopoiesis and leukemogenesis","volume":"26","author":"Argiropoulos","year":"2007","journal-title":"Oncogene"},{"issue":"6477","key":"2026071409580614000_bib43","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"issue":"10","key":"2026071409580614000_bib44","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"Kuhn","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"2026071409580614000_bib45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41588-023-01640-3","article-title":"A new genomic framework to categorize pediatric acute myeloid leukemia","volume":"56","author":"Umeda","year":"2024","journal-title":"Nat Genet"},{"issue":"12","key":"2026071409580614000_bib46","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1182\/bloodadvances.2023011771","article-title":"Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia","volume":"8","author":"van Weelderen","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2026071409580614000_bib47","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2013-03-491621","article-title":"Results of the AIEOP AML 2002\/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia","volume":"122","author":"Pession","year":"2013","journal-title":"Blood"},{"issue":"suppl 1","key":"2026071409580614000_bib48","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1182\/blood-2024-198419","article-title":"Favourable outcomes in newly diagnosed paediatric AML with gemtuzumab ozogamicin and risk-stratified therapy: results from the International Phase III Myechild 01 Trial","volume":"144","author":"Gibson","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2026071409580614000_bib49","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026071409580614000_bib50","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J Clin Invest"},{"issue":"10","key":"2026071409580614000_bib51","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Eunice","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"2026071409580614000_bib52","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12943-015-0326-0","article-title":"Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway","volume":"14","author":"Zhang","year":"2015","journal-title":"Mol Cancer"},{"issue":"1","key":"2026071409580614000_bib53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"issue":"6","key":"2026071409580614000_bib54","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/1947601910377495","article-title":"Myc roles in hematopoiesis and leukemia","volume":"1","author":"Delgado","year":"2010","journal-title":"Genes Cancer"},{"issue":"12","key":"2026071409580614000_bib55","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.exphem.2014.09.006","article-title":"Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia","volume":"42","author":"Li","year":"2014","journal-title":"Exp Hematol"},{"issue":"7370","key":"2026071409580614000_bib56","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"issue":"1","key":"2026071409580614000_bib57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10428194.2018.1464158","article-title":"MYC protein expression is an important prognostic factor in acute myeloid leukemia","volume":"60","author":"Ohanian","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2026071409580614000_bib58","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1182\/blood-2003-02-0578","article-title":"Identification of a gene expression signature associated with pediatric AML prognosis","volume":"102","author":"Yagi","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2026071409580614000_bib59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-015-2766-z","article-title":"Direct and indirect targeting of MYC to treat acute myeloid leukemia","volume":"76","author":"Brondfield","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026071409580614000_bib60","first-page":"6480","article-title":"MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation","volume":"61","author":"Silke","year":"2001","journal-title":"Cancer Res"},{"issue":"7","key":"2026071409580614000_bib61","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1158\/1535-7163.MCT-13-0576","article-title":"Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells","volume":"13","author":"Zhang","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2026071409580614000_bib62","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood.V99.9.3461","article-title":"Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK\/MAPK pathways in acute myelogenous leukemia","volume":"99","author":"Michele","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2026071409580614000_bib63","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation","volume":"387","author":"Janne","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"2026071409580614000_bib64","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2026071409580614000_bib65","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood.2025030558","article-title":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML","volume":"147","author":"Popescu","year":"2026","journal-title":"Blood"},{"issue":"6","key":"2026071409580614000_bib66","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4757\/2531136\/blooda_adv-2025-016208-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4757\/2531136\/blooda_adv-2025-016208-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:58:18Z","timestamp":1784037498000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/13\/4757\/568178\/Combining-menin-and-MEK-inhibition-to-target-poor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":66,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016208","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,14]]},"published":{"date-parts":[[2026,6,30]]}}}